Donepezil therapy in clinical practice: A randomized crossover study

Archives of Neurology

Volumn 57, Issue 1, 2000, Pages 94-99

  Greenberg, Steven M ^a,c   Tennis, Marsha K ^a   Brown, Laura B ^a   Gomez Isla, Teresa ^a   Hayden, Douglas L ^a   Schoenfeld, David A ^a   Walsh, Katie L ^a   Corwin, Claire ^b   Daffner, Kirk R ^b   Friedman, Pamela ^b   Meadows, Mary Ellen ^b   Sperling, Reisa A ^b   Growdon, John H ^a  

^a PARTNERS HEALTHCARE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; DONEPEZIL; PLACEBO;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREATITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEIZURE; SYNCOPE; VERBAL COMMUNICATION;

EID: 18544400908     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.1.94     Document Type: Article

References (24)

1. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol. 1974;30:113-121.
2. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology. 1977;27:783-790.
3. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-414.
4. Geula C, Mesulam M-M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Katzman R, Bick KL, eds. Alzheimer Disease. New York, NY: Raven Press; 1994:263-291.
5. Martin JB, Beal MF, Mazurek M, et al. Some observations on the significance of neurotransmitter changes in Alzheimer's disease. In: Terry RD, ed. Aging and the Brain. New York, NY: Raven Press; 1988:129-148.
6. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
7. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021-1031.
8. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.
9. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients tor clinical trials. J Am Geriatr Soc. 1997;45:923-928.
10. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease: Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338:506-511.
11. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein ∈4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92:12260-12264.
12. Riekkinen PJ, Soininen H, Partanen J, Paakkonen A, Helisalmi S, Riekkinen PS. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology. 1997; 129:285-288.
13. Riekkinen M, Soininen H, Riekkinen PS, et al. Tetrahydroaminoacridine improves the recency effect in Alzheimer's disease. Neuroscience. 1998;83:471-479.
14. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998;50:669-677.
15. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637-639.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
17. Blessed G, Tomlinson BE, Roth M. The assocation between quantitative measures of dementia and of senile change in the grey matter of elderly subjects. Br J Psychiatry. 1986;114:797-811.
18. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
20. Randt CT, Brown ER, Osborne DP. A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol. 1980;2:184-194.
21. Borowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135-140.
22. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA. 1998;280:1777-1782.
23. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ∈ 4 in Alzheimer's disease. Ann Neurol. 1996;39:62-70.
24. Conway EL A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Clin Neuropharmacol. 1998;21:8-17.